BC Platforms To Provide Genomic Data Management Services To Monash University In Australia
Basel, Switzerland and Helsinki, Finland - BC Platforms, a world leader in genomic data management solutions, today announced that it will partner with Monash University, Australia’s largest university and one of the top ranked in the world, to develop and improve methods for storing, retrieving, organising and analysing genomic and clinical data.
BC Platforms will provide Monash with all its core suite of products including BC¦Genome for statistical analyses within genomics, BC¦Predict for variant interpretation and BC|Safebox to safely share sensitive data between scientists at Monash and its key collaborators around the world.
BC Platforms will also support the ASPREE (ASPirin in Reducing Events in the Elderly) international clinical trial being led by the School of Public Health and Preventive Medicine at Monash and the Berman Centre for Outcomes and Clinical Research in the USA. The trial is investigating whether daily low-dose aspirin improves quality of life for older people. The randomised, double blind, placebo-controlled study for primary prevention of cardiovascular disease, dementia, depression and some cancers is being undertaken in Australia and the USA and has over 19,000 participants. Participant follow-up is conducted longitudinally for an average of five years with extensive phenotypic and clinical data collection. The ASPREE Healthy Ageing Biobank will facilitate genetic and biomarker studies across thousands of biospecimens from the study.
"We are pleased to welcome Monash University as a customer in our global network of leading research units. Monash clearly is among those entities who can drive and impact the whole healthcare industry with their innovative capabilities including the unique ASPREE initiative,” said Nino da Silva, EVP, Sales and Marketing at BC Platforms.
“Our primary goal is to deliver a platform to the University that will provide researchers worldwide with timely and easy to access large-scale data sets in order to bring clinical benefits to patients.”
Dr Paul Lacaze, Head of the Public Health Genomics Program in the School of Public Health and Preventive Medicine at Monash, commented: “We are delighted to partner with BC Platforms and believe that with their support we can now tackle a more ambitious range of epidemiological, clinical and genetic research questions. This will require analysing data sets of increasing size and scale as our research program continues to grow in coming years.”
- END -
Notes to editors:
About Monash University Faculty of Medicine Nursing and Health Sciences
Monash University Faculty of Medicine Nursing and Health Sciences is dedicated to the pursuit of excellence and innovation in research and teaching. It aspires to leadership in all areas of research activity, and advocacy for policy – locally, nationally and internationally – to improve health and social outcomes and health inequalities. The Faculty is committed to maintaining Monash University as a leading international medical research university, recognised for the breadth and depth of its research, for its opportunities and commitment to postgraduate training, and as a thriving biotechnology hub. The Faculty is committed to the translation of biomedical and public health research to health outcomes in partnership with affiliated health care facilities and Medical Research Institutes. For more information please visit http://www.med.monash.edu.au/
About BC Platforms
BC Platforms is a world leader in providing powerful genomic data management solutions to address some of the biggest healthcare challenges today by leveraging the convergence of genomics and healthcare information technologies. Our high performing genomic data management platform enables flexible data integration, secure analysis and interpretation of molecular and clinical information. BC Platforms' vision is to revolutionize decision making in drug development to bring clinical benefits to patients. Founded in 1997, the Company has a strong scientific heritage underpinned by 18 years of working in close collaboration with a network of leading researchers, developers, manufacturers and vendors.
We currently provide solutions to over 50 leading international institutions in 18 countries including top-tier academic and hospital research groups, major pharmaceutical and agricultural companies. Our management team consists of industry leaders with over 90 years of combined experience in life sciences, computational biology and industrial technology. BC Platforms has global operations with its headquarters in Basel, Switzerland, research and development located in Helsinki, Finland, and sales and marketing based in London, Boston, and Vancouver. For more information, please visit www.bcplatforms.com or follow us on Twitter @BCPlatforms.
BC Platforms will provide Monash with all its core suite of products including BC¦Genome for statistical analyses within genomics, BC¦Predict for variant interpretation and BC|Safebox to safely share sensitive data between scientists at Monash and its key collaborators around the world.
BC Platforms will also support the ASPREE (ASPirin in Reducing Events in the Elderly) international clinical trial being led by the School of Public Health and Preventive Medicine at Monash and the Berman Centre for Outcomes and Clinical Research in the USA. The trial is investigating whether daily low-dose aspirin improves quality of life for older people. The randomised, double blind, placebo-controlled study for primary prevention of cardiovascular disease, dementia, depression and some cancers is being undertaken in Australia and the USA and has over 19,000 participants. Participant follow-up is conducted longitudinally for an average of five years with extensive phenotypic and clinical data collection. The ASPREE Healthy Ageing Biobank will facilitate genetic and biomarker studies across thousands of biospecimens from the study.
"We are pleased to welcome Monash University as a customer in our global network of leading research units. Monash clearly is among those entities who can drive and impact the whole healthcare industry with their innovative capabilities including the unique ASPREE initiative,” said Nino da Silva, EVP, Sales and Marketing at BC Platforms.
“Our primary goal is to deliver a platform to the University that will provide researchers worldwide with timely and easy to access large-scale data sets in order to bring clinical benefits to patients.”
Dr Paul Lacaze, Head of the Public Health Genomics Program in the School of Public Health and Preventive Medicine at Monash, commented: “We are delighted to partner with BC Platforms and believe that with their support we can now tackle a more ambitious range of epidemiological, clinical and genetic research questions. This will require analysing data sets of increasing size and scale as our research program continues to grow in coming years.”
- END -
Notes to editors:
About Monash University Faculty of Medicine Nursing and Health Sciences
Monash University Faculty of Medicine Nursing and Health Sciences is dedicated to the pursuit of excellence and innovation in research and teaching. It aspires to leadership in all areas of research activity, and advocacy for policy – locally, nationally and internationally – to improve health and social outcomes and health inequalities. The Faculty is committed to maintaining Monash University as a leading international medical research university, recognised for the breadth and depth of its research, for its opportunities and commitment to postgraduate training, and as a thriving biotechnology hub. The Faculty is committed to the translation of biomedical and public health research to health outcomes in partnership with affiliated health care facilities and Medical Research Institutes. For more information please visit http://www.med.monash.edu.au/
About BC Platforms
BC Platforms is a world leader in providing powerful genomic data management solutions to address some of the biggest healthcare challenges today by leveraging the convergence of genomics and healthcare information technologies. Our high performing genomic data management platform enables flexible data integration, secure analysis and interpretation of molecular and clinical information. BC Platforms' vision is to revolutionize decision making in drug development to bring clinical benefits to patients. Founded in 1997, the Company has a strong scientific heritage underpinned by 18 years of working in close collaboration with a network of leading researchers, developers, manufacturers and vendors.
We currently provide solutions to over 50 leading international institutions in 18 countries including top-tier academic and hospital research groups, major pharmaceutical and agricultural companies. Our management team consists of industry leaders with over 90 years of combined experience in life sciences, computational biology and industrial technology. BC Platforms has global operations with its headquarters in Basel, Switzerland, research and development located in Helsinki, Finland, and sales and marketing based in London, Boston, and Vancouver. For more information, please visit www.bcplatforms.com or follow us on Twitter @BCPlatforms.